These studies suggest that alterations in genes (mostly amplification by copy number of genes, RNA or protein) coding for TIMPs and MMPs, even though in low numbers, changes the status of the platinum response in ovarian cancer patients; more becoming sensitive to platinum therapy with TIMP-2 and -3 mutations while this is reversed for MMP-2 and -11 mutations. Here, MMP2 is linked to ovarian carcinoma.